Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AD-109 in Mild to Moderate Obstructive Sleep Apnea
NCT04631107Phase 2Completed
- Sponsor
- Apnimed, Inc.
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aroxybutynin and atomoxetine in obstructive sleep apnea (OSA) (6 arms), sponsored by Apnimed, Inc. Primary endpoints: Change in Hypoxic Burden (HB) Log Transformed - Log10HB[(%*Min)/h] and Change in Hypoxic Burden (HB) Raw Values - HB[(%*Min)/h]. Started Dec 2020; status: completed.
02
Drugs
aroxybutyninatomoxetine
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT04631107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631107.